- $1.30bn
- $1.37bn
- $388.15m
- 62
- 25
- 92
- 62
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 408 | 585 | 645 | 459 | 388 |
Cost of Revenue | |||||
Gross Profit | 119 | 160 | 102 | 70.1 | 66.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 383 | 565 | 643 | 494 | 429 |
Operating Profit | 24.8 | 19.5 | 2.15 | -35.4 | -41.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 17.8 | 9.29 | -9.52 | 30.5 | -57 |
Provision for Income Taxes | |||||
Net Income After Taxes | 17.8 | 10.6 | -8.47 | -72.4 | -56.6 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 17.8 | 14.8 | -5.28 | -57.7 | -40.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 17.8 | -4.37 | -5.28 | -57.7 | -40.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.36 | 1.32 | -0.156 | -1.37 | -0.784 |
Dividends per Share |